arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

biote Corp.

BTMD
$1.31 ▼ -0.01 (-0.76%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
23 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

biote Corp. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $37.5M
Dividend Yield —
Revenue Growth -9.5% ↘
Op. Margin -7.9% ↘
ROIC -6.2% ↘
FCF / Share $-0.13 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -1.90
info Valuation on last close. End-of-day price, Sep 23, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.23M
↓ -9.5% —
Net Income Profit after all expenses
$-6.56M
↓ -388.2% —
Operating Margin Operating profit as % of sales
-7.9%
↓ -212.6% 73th
FCF / Share Free cash flow per share
$-0.13
↓ -212.9% —
Long-Term Debt Long-term obligations
$125.00M
↑ +23.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
74
Returns
18
Financial Health ↓
86
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 6 years · 23 quarters